In its Q215 earnings release, Athersys provided much needed additional data with regard to its Phase II MultiStem trial in ischaemic stroke, which had missed the primary endpoint. Changes in the trial design aimed at accelerating enrolment led to the inclusion of patients both less likely to respond to MultiStem and more likely to respond to standard of care. If the original trial design had been in place, the additional data suggest the trial may have been positive. Our fair value increases
19 Aug 2015
More clarity on ischaemic stroke
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
More clarity on ischaemic stroke
In its Q215 earnings release, Athersys provided much needed additional data with regard to its Phase II MultiStem trial in ischaemic stroke, which had missed the primary endpoint. Changes in the trial design aimed at accelerating enrolment led to the inclusion of patients both less likely to respond to MultiStem and more likely to respond to standard of care. If the original trial design had been in place, the additional data suggest the trial may have been positive. Our fair value increases